Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Ultra-deep next-generation sequencing has emerged in recent years as an important
diagnostic tool for the detection and follow-up of tumor burden in most of the known …

Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …

Standardizing response criteria for myelodysplastic syndromes (MDS), a clinically and
biologically heterogeneous group of disorders, has been historically challenging. The …

Monitoring minimal residual disease (MRD) provides important information during treatment
of hematologic malignancies. Chimerism analysis also provides key information after …

Simple Summary Single-cell DNA sequencing is a laboratory technique that analyzes the
genetic content of individual cells. In the context of genetically diverse hematological …

Simple Summary Monitoring the response to treatment in hematologic malignancies is
essential in defining the best way to optimize patient management. In general, achieving a …

Allo-HSCT remains the standard of care for high-risk AML. Increased access to transplant,
reduced toxicity and relapse are improving patient outcomes. Further research is needed to …

Chronic myelomonocytic leukemia (CMML) is an aggressive disease in which survival after
allogeneic hematopoietic stem cell transplantation (HCT) remains relatively poor. An …

Introduction: Donor lymphocyte infusion (DLI) is one of the effective options for post-
transplant disease control of myelodysplastic syndrome (MDS). Its success or failure …